BUHLMANN CORP

Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease

May 22, 2017
BÜHLMANN Quantum Blue® fCAL extended Citation: Rodriguez, A. et al.  Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. World J Gastrointest Pharmacol Ther 8(2):127-130. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.127. Highlight from this Publication “In summary, we present the first correlation study of rapid POC calprotectin testing in a pediatric IBD
Read more

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

October 3, 2016
BÜHLMANN Quantum Blue® fCAL Citation: Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663. Highlight from this Publication "The FC test effected a change in management 51.3% of the time and receipt of the result was associated with a reduction
Read more

Fecal Calprotectin in Healthy Children Aged 1-4 Years

August 19, 2016
BÜHLMANN fCAL® ELISA Citation: Zhu, Q,Feng Li, Junli Wang, Lixiao Shen, Xiaoyang Sheng. Fecal Calprotectin in Healthy Children Aged 1-4 Years, PLOS ONE. 2016. http://dx.doi.org/10.1371/journal.pone.0150725. “Children aged from 1 to 4 years old have lower FC concentrations compared with healthy infants (<1years), and higher FC concentrations when comparing with children older than 4 years and adults.” Learn More
Read more